BRIEF: Fanhua’s revenue down sharply on falling commission rates

FANH.US

Financial services provider Fanhua Inc. (FANH.US) reported on Wednesday its revenue fell 42.7% in the first half of 2024 to 1.12 billion yuan ($158 million), blaming falling commission rates and sales volume for the decline. Its profit plummeted over the period to 4.74 million yuan from 137 million yuan a year earlier.

The company’s total gross written premiums for its life insurance business fell 0.7% year-on-year to 8.64 billion yuan in the last six-month period. Its first-year premiums fell by a much larger 48% to 1.2 billion yuan, but that was mostly offset by a 16.7% rise in revenue from its renewal premiums.

Fanhua gets the big majority of its revenue from its core insurance brokerage business, though it is trying to diversify into other financial services. The company’s stock fell 4.6% in after-hours trade after it published its latest financial report on Thursday after market close.

By Doug Young

To subscribe to Bamboo Works free weekly newsletter, click here

,

Related Articles

RELATED ARTICLES

  1. Shouhui pushes for protective IPO as risk factors multiply
    Shouhui pushes for protective IPO as risk factors multiply  
  2. Dida reverses into revenue contraction, falling profits
    2559.HK
  3. Baige flies into IPO on demand for its popular – but costly – insurance risk services
Discover hidden China stock gems in our weekly newsletter

Follow us

Facebook Twitter Linkedin Weixin Weibo Youtube

Subscribe to Our Free eNewsletter

Subscribe

Check out our content with some of our syndication partners

factiva

Recent Articles

Kelun-Biotech reported rising sales of its signature cancer drug

Precision cancer drugs show promise for Kelun-Biotech

The company reported rising sales of its signature cancer drug and could get national insurance coverage for other key products, potentially boosting full-year earnings Key Takeaways: Topline revenue actually fell…
6990.HK
Illustration of China's hydrogen battery industry

China plays defense on EV batteries, offense on hydrogen

China rolls out new rules restricting the export of cutting-edge technology for EV battery manufacturing. How will this affect Chinese battery makers setting up factories abroad? And hydrogen fuel cell maker Refire reports its revenue fell 10% in the first half of the year. What does this say about a Chinese sector that's getting huge government support, but has yet to find a mass audience?
3750.HK 2570.HK